Cardiff Oncology, Inc.CRDF
Oncology14 cited findings · profile updated 2026-08-20
0.90 USDnot live — refreshed daily
About Cardiff Oncology, Inc.
Cardiff Oncology, Inc. (CRDF) is an oncology-focused research site. The company's drug candidate CRDF-004 is in Phase 2 development. A meeting regarding CRDF-004 had a successful outcome, and a planned trial initiation is set for Q1 2027 or the first quarter of 2027.
In studies of CRDF-004, a confirmed ORR of 72.2% and 42.1% was observed, representing an ORR improvement of 30%. The drug demonstrated a PFS HR (BICR) of 0.55 and a PFS HR (IA) of 0.57. No additive adverse events were noted for CRDF-004. Currently, 12 patients remain on trial for CRDF-004, with 8 patients remaining on onvansertib arms and 1 patient remaining on the SoC arm.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Confirmed ORR | 72.2% | Cardiff Oncology, Inc. — SEC 8-K (2026-08-11), p.2 |
| Confirmed ORR | 42.1% | Cardiff Oncology, Inc. — SEC 8-K (2026-08-11), p.2 |
| ORR improvement | 30% | Cardiff Oncology, Inc. — SEC 8-K (2026-08-11), p.2 |
| PFS HR (BICR) | 0.55 | Cardiff Oncology, Inc. — SEC 8-K (2026-08-11), p.2 |
| PFS HR (IA) | 0.57 | Cardiff Oncology, Inc. — SEC 8-K (2026-08-11), p.2 |
| Additive adverse events | no | Cardiff Oncology, Inc. — SEC 8-K (2026-08-11), p.2 |
Key projects
- CRDF-004
CRDF-004 is in Phase 2 development, with a planned trial initiation in Q1 2027.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →